The Study of Antidepressant Properties and Safety of Fer-01(Soline®) on the Patients With Depression

Overview

Considering the potential modulatory effects of Salvia divinorum, Lycium, Chenpi and Dihuang supplementation on mood, this study is a clinical study of Soline® (product mixed with Salvia divinorum, Lycium, Chenpi and Dihuang ) supplementation to investigate the effect of attenuating the occurrence of depression. The study will enroll 100 patients who meet the inclusion and exclusion criteria. The trial will be concluded when a total of evaluable 80 patients (40 patients in each treatment group).

Full Title of Study: “Phase IIa Study of Antidepression Use Natural Plants Extracted of Soline Capsule.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 2013

Detailed Description

Depression is one of the major metal disorders associated with symptoms such as regular negative moods, decreased physical activities, feeling of helplessness, and cognitive deficits. According to the seminal "burden of disease" study by World Health Organization (WHO) has predicted that by 2030 depression will be the second leading cause of disease. The Diagnostic and Statistical Manual of Mental Disorders (DSM) is the American Psychiatric Association's standard reference for psychiatry which includes over 400 different definitions of mental disorders. Selective and reversible monoamine oxidase inhibitor, selective serotonin reuptake inhibitors or serotonin and noradrenaline reuptake inhibitors are the typical antidepressants usually. Unfortunately, current drug therapies for depression are not ideal. Most of the drugs are synthetic nitrogen-bearing compounds which have inevitably some serious adverse-effects such as causing cardiovascular disease, insomnia and ovarian teratomas. Hence, there is an urgent need for the research and development of more effective antidepressants without any/ with minor adverse-effect. Up to the present, many Chinese medicinal plants have been successfully used to treat sentimental diseases, which is similar to depression in the Western medicine. Shamans of the Mazatec people of Oaxaca, Mexico have used Salvia divinorum for at least centuries in ethnomedical practices including spiritual healing and divinorum. Salvia divinorum contains the known psychoactive constituent salvinorin A, which is a trans-neoclerodancediterpenoid and a к-opioid agonist with no activity at the 5-HT2A serotonin receptor, making it an ideal agent for antidepressant. Salvia divinorum use occurring in Europe and Japan, and survey research suggests that user claim positive after-effects. Lycium, Chenpi ( Citrus reticulate Blanco ) and Dihuang ( Rehmannia glutinosa ) were widely used in the vast majority of Chinese medicine prescription to treat mental disease, for example, Lily Bulb Decoction to Preserve the Lung ( Lycium and Dihuang ) from Analytic Collection of Medical Formula , Spirit-quieting Decoction ( Chenpi ) form Restoring Health from Tens of Thousands of Diseases. Considering the potential modulatory effects of Salvia divinorum, Lycium, Chenpi and Dihuang supplementation on mood, this study is a clinical study of Soline® (product mixed with Salvia divinorum, Lycium, Chenpi and Dihuang ) supplementation to investigate the effect of attenuating the occurrence of depression.

Interventions

  • Other: Soline capsule

Arms, Groups and Cohorts

  • Soline capsule
    • Salvia divinorum, Lycium, Chenpi and Dihuang

Clinical Trial Outcome Measures

Primary Measures

  • DSM-IV
    • Time Frame: Day 1 and up to 6 weeks
    • diagnosis of major depressive disorder according to DSM-Ⅳ has change

Secondary Measures

  • analysis of inflammation cytokine
    • Time Frame: Day 1 and up to 6 weeks
    • Laboratory examination parameters ( TNF-a,IL-6, TGF-b1)
  • analysis of basic biochemical
    • Time Frame: Day 1 and up to 6 weeks
    • The incidence of hepatic and renal adverse events(GOT, GTP, BUN, creatinine…)
  • Fatty acid composition
    • Time Frame: Day 1 and up to 6 weeks
    • Fatty acid composition is measure with gas chromatography.

Participating in This Clinical Trial

Inclusion Criteria

•Clinical diagnosis of major depressive disorder

Exclusion Criteria

  • Pregnancy and nursing
  • Schizophrenia spectrum disorder
  • Manic depressive disorder
  • Bipolar disorder
  • Anxiety Disorder
  • Abnormal biochemistry analysis value:( AST and ALT≧triple the upper limit of normal);
  • Serum creatinine>2mg/dl
  • BUN>40mg/dL
  • Total bilirubin>2.0mg/dL
  • Hematocrit<30
  • White blood count≧15000
  • High sensitivity to this product
  • The diseases will influence of results: pulmonary tuberculosis, uncontrolled diabetes, uncontrolled hypertension, serious infection and critical cardiovascular, liver, kidney disease.
  • Alcohol abuse or drug abuse
  • Attended the other study in last 4 weeks
  • Attempted suicide or self-injurious

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Taipei Medical University Hospital
  • Collaborator
    • Taipei Medical University Shuang Ho Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shih-Yi Huang, Ph.D, Principal Investigator, Taipei Medical University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.